PrimeGen Biotech is dedicated to the research and therapeutic applications of adult stem cells, leading to individualized patient therapies.  Entering its fifth year of operations at the pre-clinical stage of product development, the company specializes in two core technologies: germ line stem cells and therapeutic reprogramming.  Pioneering work on induced pluripotent stem cells (iPS cells) positions PrimeGen as a leader in moving this breakthrough technology from research to therapy.  Future applications of both PrimeGen core technologies will enlist a patient’s own adult tissue cells to generate stem cells for regenerative and restorative medical treatments.

Based in Irvine, California, PrimeGen Biotech is a privately held, Delaware limited liability company.  PrimeGen Biotech LLC is also the parent company of its two subsidiaries: PrimeCell Therapeutics LLC and NewStem Biosciences LLC.